Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Martyn Greenacre Insider Profile
4 Followers
Martyn Greenacre, Director at Lisata Therapeutics, holds 26.09K shares in Curis (Ticker: CRIS), holds 88.53K shares in Lisata Therapeutics (Ticker: LSTA).
Martyn Greenacre has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Martyn Greenacre holds in companies
Most Profitable Insider Trade
The most profitable trade made by Martyn Greenacre
Martyn Greenacre's Trading History
Lisata Therapeutics
Jun 04, 2015
Director
Uninformative Buy
―
$245.67K
Curis
Jan 25, 2019
Director
Uninformative Sell
19.43K
$408.55K
List of latest transactions for each holding click on a transaction to see Martyn Greenacre's performance on stock
You May Also Like
Martyn Greenacre insider profile FAQ
What is the percentage of profitable transactions made by Martyn Greenacre?
The percentage of profitable transactions made by Martyn Greenacre is ―.
What is the average return per transaction made by Martyn Greenacre?
The average return per transaction made by Martyn Greenacre is ―.
What stocks does Martyn Greenacre hold?
Martyn Greenacre holds: LSTA, CRIS stocks.
What was Martyn Greenacre’s latest transaction?
Martyn Greenacre latest transaction was an Uninformative Sell of $19.43K.
What was Martyn Greenacre's most profitable transaction?
Martyn Greenacre’s most profitable transaction was an Informative Sell of CRIS stock on May 27, 2016. The return on the trade was -1.10%.
What is Martyn Greenacre's role in Lisata Therapeutics?
Martyn Greenacre's role in Lisata Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.